| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.84M | 2K | 323K | 821K | 198K |
| Revenue Growth % | - | - | -1% | 160.5% | 1.54% | -0.76% |
| Cost of Goods Sold | 369K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -369K | 1.84M | 2K | 323K | 821K | 198K |
| Gross Margin % | - | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 5.98% | -1% | 160.5% | 1.54% | -0.76% |
| Operating Expenses | 24.38M | 42.48M | 50.86M | 45.4M | 54.83M | 42.33M |
| OpEx % of Revenue | - | 23.11% | 25429.5% | 140.57% | 66.79% | 213.81% |
| Selling, General & Admin | 5.94M | 11.04M | 15.29M | 9.95M | 20.64M | 17.77M |
| SG&A % of Revenue | - | 6.01% | 7645.5% | 30.8% | 25.14% | 89.74% |
| Research & Development | 18.44M | 31.44M | 35.57M | 35.46M | 34.19M | 24.57M |
| R&D % of Revenue | - | 17.11% | 17784% | 109.77% | 41.65% | 124.07% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.75M | -40.65M | -50.86M | -45.08M | -54.01M | -42.14M |
| Operating Margin % | - | -22.11% | -25428.5% | -139.57% | -65.79% | -212.81% |
| Operating Income Growth % | - | -0.64% | -0.25% | 0.11% | -0.2% | 0.22% |
| EBITDA | -24.38M | -40.51M | -50.7M | -44.9M | -53.91M | -42.06M |
| EBITDA Margin % | - | -22.04% | -25352% | -139.01% | -65.66% | -212.44% |
| EBITDA Growth % | - | -0.66% | -0.25% | 0.11% | -0.2% | 0.22% |
| D&A (Non-Cash Add-back) | 369K | 137K | 153K | 182K | 103K | 72K |
| EBIT | -45.71M | -40.65M | -50.27M | -44.06M | -53.55M | -41.13M |
| Net Interest Income | 656K | 258K | 384K | 338K | 603K | 301K |
| Interest Income | 702K | 330K | 467K | 431K | 753K | 480K |
| Interest Expense | 46K | 72K | 83K | 93K | 150K | 179K |
| Other Income/Expense | -21M | -34.26M | -43.94M | -195.73M | -118.58M | -11.46M |
| Pretax Income | -45.75M | -74.91M | -94.8M | -240.81M | -172.59M | -53.6M |
| Pretax Margin % | - | -40.75% | -47398% | -745.54% | -210.22% | -270.7% |
| Income Tax | 153K | -85K | 1K | 1K | 10K | 259K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -45.91M | -74.82M | -94.8M | -240.81M | -172.6M | -53.86M |
| Net Margin % | - | -40.71% | -47398.5% | -745.54% | -210.23% | -272.01% |
| Net Income Growth % | - | -0.63% | -0.27% | -1.54% | 0.28% | 0.69% |
| Net Income (Continuing) | -45.91M | -74.82M | -94.8M | -240.81M | -172.6M | -53.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53 | -20.70 | -23.45 | -61.60 | -231.99 | -52.80 |
| EPS Growth % | - | -38.06% | -0.13% | -1.63% | -2.77% | 0.77% |
| EPS (Basic) | -0.53 | -20.70 | -23.45 | -61.60 | -231.99 | -52.80 |
| Diluted Shares Outstanding | 867.96K | 867.96K | 867.96K | 867.96K | 743.97K | 926.47K |
| Basic Shares Outstanding | 867.96K | 867.96K | 867.96K | 867.96K | 743.97K | 926.47K |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 75.43M | 156.71M | 99.37M | 55.79M | 39.92M | 10.27M |
| Cash & Short-Term Investments | 74.12M | 154.39M | 94.48M | 54.61M | 37.82M | 9.77M |
| Cash Only | 38.49M | 130.65M | 46.74M | 32.67M | 32.06M | 9.77M |
| Short-Term Investments | 35.63M | 23.74M | 47.74M | 21.94M | 5.76M | 0 |
| Accounts Receivable | 361K | 415K | 506K | 547K | 466K | 127K |
| Days Sales Outstanding | - | 82.41 | 92.34K | 618.13 | 207.17 | 234.12 |
| Inventory | 0 | 0 | 2.25M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 140K | 122K | 120K | 0 | 7K | 0 |
| Total Non-Current Assets | 3.62M | 13.23M | 24.07M | 20.68M | 15.46M | 2.83M |
| Property, Plant & Equipment | 2.01M | 1.87M | 1.32M | 1.48M | 586K | 1.02M |
| Fixed Asset Turnover | - | 0.98x | 0.00x | 0.22x | 1.40x | 0.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.34M | 10.32M | 14.8M | 14.78M | 14.76M | 1.74M |
| Long-Term Investments | 0 | 0 | 7.84M | 4.31M | 0 | 0 |
| Other Non-Current Assets | 96K | 1.04M | 113K | 124K | 119K | 75K |
| Total Assets | 79.05M | 169.94M | 123.44M | 76.47M | 55.39M | 13.1M |
| Asset Turnover | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.02x |
| Asset Growth % | - | 1.15% | -0.27% | -0.38% | -0.28% | -0.76% |
| Total Current Liabilities | 4.58M | 12.08M | 13.56M | 12.36M | 13.56M | 7.4M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 768K | 3.76M | 2.15M | 0 | 4.24M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.62M | 6.72M | -508K | 68K | 0 | 0 |
| Current Ratio | 16.48x | 12.97x | 7.33x | 4.51x | 2.95x | 1.39x |
| Quick Ratio | 16.48x | 12.97x | 7.16x | 4.51x | 2.95x | 1.39x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 135.2M | 285.79M | 322.74M | 512.24M | 597K | 835K |
| Long-Term Debt | 133.97M | 284.79M | 322.21M | 0 | 0 | 0 |
| Capital Lease Obligations | 1.23M | 999K | 528K | 377K | 267K | 733K |
| Deferred Tax Liabilities | 0 | 0 | -3.62M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 511.86M | 330K | 102K |
| Total Liabilities | 139.78M | 297.87M | 336.3M | 524.6M | 14.15M | 8.23M |
| Total Debt | 135.97M | 289.55M | 325.41M | 991K | 4.66M | 966K |
| Net Debt | 97.48M | 158.91M | 278.67M | -31.68M | -27.39M | -8.8M |
| Debt / Equity | - | - | - | - | 0.11x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -538.00x | -564.53x | -612.73x | -484.74x | -360.09x | -235.40x |
| Total Equity | -60.72M | -127.93M | -212.86M | -448.12M | 41.23M | 4.86M |
| Equity Growth % | - | -1.11% | -0.66% | -1.11% | 1.09% | -0.88% |
| Book Value per Share | -69.96 | -147.40 | -245.24 | -516.29 | 55.42 | 5.25 |
| Total Shareholders' Equity | -60.72M | -127.93M | -212.86M | -448.12M | 41.23M | 4.86M |
| Common Stock | 36K | 39K | 40K | 41K | 9K | 11K |
| Retained Earnings | -66.73M | -141.54M | -235.44M | -474.6M | -646.97M | -700.82M |
| Treasury Stock | 0 | 0 | -1.65M | -68K | 0 | 0 |
| Accumulated OCI | 251K | 5.08M | 12.29M | 3.4M | 26.72M | 3.44M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -21.94M | -35.68M | -43.31M | -42.82M | -43.21M | -28.74M |
| Operating CF Margin % | - | -19.41% | -21656% | -132.58% | -52.63% | -145.17% |
| Operating CF Growth % | - | -0.63% | -0.21% | 0.01% | -0.01% | 0.33% |
| Net Income | -45.91M | -74.82M | -94.8M | -240.81M | -172.6M | -53.86M |
| Depreciation & Amortization | 369K | 4.39M | 681K | 775K | 669K | 361K |
| Stock-Based Compensation | 0 | 4.51M | 8.12M | 3.58M | 12.69M | 10.93M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 22.48M | 31.18M | 43.13M | 189.98M | 116.97M | 12.22M |
| Working Capital Changes | 1.11M | -940K | -453K | 3.65M | -932K | 1.61M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -29.86M | 2.33M | -38.95M | 29.05M | 21.36M | 5.98M |
| Capital Expenditures | -857K | -144K | -50K | -367K | -6K | -24K |
| CapEx % of Revenue | - | 0.08% | 25% | 1.14% | 0.01% | 0.12% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -5K | 2.47M | -38.9M | 29.42M | 21.37M | 6.01M |
| Cash from Financing | 9.51M | 125.51M | -1.64M | -294K | 21.23M | 468K |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | -311K | -72K | -83K | -93K | 4.11M | -4.41M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -22.8M | -35.82M | -43.36M | -43.19M | -43.22M | -28.77M |
| FCF Margin % | - | -19.49% | -21681% | -133.72% | -52.64% | -145.29% |
| FCF Growth % | - | -0.57% | -0.21% | 0% | -0% | 0.33% |
| FCF per Share | -26.27 | -41.28 | -49.96 | -49.76 | -58.09 | -31.05 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.48x | 0.46x | 0.18x | 0.25x | 0.53x |
| Interest Paid | 0 | 72K | 83K | 93K | 122K | 193K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | -418.59% | -233.67% |
| Return on Invested Capital (ROIC) | -50.5% | -90.02% | -78.82% | - | -292.72% | -638.23% |
| Gross Margin | - | 100% | 100% | 100% | 100% | 100% |
| Net Margin | - | -4070.73% | -4739850% | -74554.49% | -21023.26% | -27201.01% |
| Debt / Equity | - | - | - | - | 0.11x | 0.20x |
| Interest Coverage | -538.00x | -564.53x | -612.73x | -484.74x | -360.09x | -235.40x |
| FCF Conversion | 0.48x | 0.48x | 0.46x | 0.18x | 0.25x | 0.53x |
| Revenue Growth | - | - | -99.89% | 16050% | 154.18% | -75.88% |
Apollomics, Inc. (APLM) reported $1.0M in revenue for fiscal year 2024.
Apollomics, Inc. (APLM) saw revenue decline by 75.9% over the past year.
Apollomics, Inc. (APLM) reported a net loss of $226.5M for fiscal year 2024.
Apollomics, Inc. (APLM) has a return on equity (ROE) of -233.7%. Negative ROE indicates the company is unprofitable.
Apollomics, Inc. (APLM) had negative free cash flow of $72.0M in fiscal year 2024, likely due to heavy capital investments.